SCHEMBL480655

SCHEMBL480655

COC(=O)c1ccc2c(c1)NC(=O)C2=C(Nc1ccc(C(C)(C)N)c(Br)c1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
AURKA O14965 1/20 0.39
RAF1 P04049 1/20 0.39
NOTUM Q6P988 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RAB9A P51151 2/20 0.38
BRD4 O60885 2/20 0.38
BRD2 P25440 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
PDPK1 O15530 1/20 0.36
BACE1 P56817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480445 0.91 RXFP1 (0.45) KMT2ATP53POLBTHRBRAB9A
SCHEMBL2121532 0.91 KMT2A (0.40) KMT2ACTDSP1AURKARAF1TP53
SCHEMBL479436 0.90 MAPT (0.40) KMT2ACTDSP1AURKARAF1TP53
SCHEMBL479595 0.90 BRD4 (0.40) KMT2ACTDSP1TP53POLBTHRB
SCHEMBL479448 0.90 KMT2A (0.39) KMT2ACTDSP1AURKARAF1TP53
SCHEMBL479616 0.89 NOTUM (0.40) KMT2ACTDSP1AURKARAF1NOTUM
SCHEMBL480718 0.89 KMT2A (0.38) KMT2ACTDSP1AURKARAF1TP53
SCHEMBL480387 0.87 CASP3 (0.39) KMT2ACTDSP1TP53POLBTHRB
SCHEMBL2568537 0.87 KMT2A (0.43) KMT2ACTDSP1TP53POLBTHRB
SCHEMBL19133985 0.86 HTT (0.41) KMT2ACTDSP1TP53POLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9844572-B2 Promotion of neuronal integration in neural stem cell grafts LIFE & BRAIN GMBH (DE) 2017-12-19 US disclosed
EP-2411034-B1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2017-07-26 EP disclosed
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2012-04-19 US disclosed
EP-2411034-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS Life & Brain GmbH (DE) 2012-02-01 EP disclosed
WO-2010108665-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS DCX, NGF, BDNF KMT2A 3904/4885CTDSP1 4624/4885AURKA 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.